Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 3/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22262021 | 0.87 | RXRA (0.43) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL22262022 | 0.87 | RXRA (0.43) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL20116867 | 0.84 | NQO2 (0.46) | RXRARXRBRXRGATRSCN9A | |
| SCHEMBL28703847 | 0.81 | RXRA (0.40) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL28703846 | 0.81 | RXRA (0.40) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL31178830 | 0.80 | CYP11B2 (0.35) | RXRARXRBRXRGATRCACNA1B | |
| SCHEMBL31161177 | 0.78 | RXRA (0.37) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL19502544 | 0.78 | RXRA (0.41) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL1760288 | 0.76 | RXRA (0.43) | RXRARXRBRXRGSCN9ACYP4F2 | |
| SCHEMBL22941287 | 0.76 | RXRA (0.45) | RXRARXRBRXRGATRSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383895-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2024-11-21 | — | — | US | disclosed |
| US-12077530-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2024-09-03 | — | — | US | disclosed |
| EP-3640251-B1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2021-12-08 | — | — | EP | disclosed |
| US-20210284636-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2021-09-16 | — | — | US | disclosed |
| US-10961241-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| US-20200239467-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| EP-3640251-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2020-04-22 | — | — | EP | disclosed |
| US-10590130-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-17 | — | — | US | disclosed |
| EP-3433256-B1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVE USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2019-08-07 | — | — | EP | disclosed |
| US-20190100520-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2019-04-04 | — | — | US | disclosed |
| WO-2018077630-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-26 | — | — | US | disclosed |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239467-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | RXRA 380/4885RXRB 311/4885RXRG 283/4885 |
| US-10961241-B2 | Chemical compounds | MKI67, CCNI, MCL1 | RXRA 380/4885RXRB 311/4885RXRG 283/4885 |
| US-12077530-B2 | Chemical compounds | MKI67, CCNI, MCL1 | RXRA 380/4885RXRB 311/4885RXRG 283/4885 |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | RXRA 380/4885RXRB 311/4885RXRG 283/4885 |
| US-20190100520-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | RXRA 380/4885RXRB 311/4885RXRG 283/4885 |
| US-10590130-B2 | Chemical compounds | MKI67, CCNI, MCL1 | RXRA 380/4885RXRB 311/4885RXRG 283/4885 |
| US-20210284636-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | RXRA 380/4885RXRB 311/4885RXRG 283/4885 |
| US-20240383895-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | RXRA 380/4885RXRB 311/4885RXRG 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.